The matter pertains to Daiichi Sankyo's challenge to the Fortis-IHH deal. The Japanese company had filed the case to recover the Rs 3,600 c...

With its own mixed track record in India, the coup can easily turn into a winner’s curse for IHH.

The company’s promoters, Malvinder and Shivinder Singh, who are engaged in a legal battle with Japanese pharmaceutical major Daichi Sankyo,...

Oscar Traders was one of 20 respondents linked to the brothers from whom Daiichi is trying to recover the money awarded to it by a Singapor...

The 2005-07 period saw 6 sharp corrections with average decline of 15%, while the market over this entire period gave 190% returns.

India is now keen on drawing investments into the pharmaceuticals segment to reduce dependence on China for bulk drugs.

Ranbaxy pared most of its morning gains and was trading 1.6 per cent lower at Rs 452.05. It hit a low of Rs 445 and a high of Rs 505 in tra...

The Sun-Ranbaxy combined entity will unlock the true potential of the Gurgaon based company, says former Ranbaxy owner Malvinder Singh.

The deal values Ranbaxy shares at Rs 457 apiece, representing an 18 per cent premium to their 30-day volume-weighted average share price.

FDA has named at least five Indian companies among 43 drugmakers that have failed to meet their annual facility fee payment obligations.

Ranbaxy Laboratories' net profit grew more than two-and-a-half times in its third quarter ended September 30, 2010. The initial euphoria to...

The promoters of Super Religare Laboratories Malvinder and Shivinder Singh may buyout Piramal Heathcare’s 10% stake in the country’s larges...

FDI inflows declined 26% in October this year compared to the same month last year, commerce minister Kamal Nath told the Lok Sabha on Tues...

Foreign investment in the country’s industrial and other firms has surged to nearly $22 billion during the first six months of the year, wi...

The Japanese company planned to run a full-fledged operations in India and had long-terms plans for India.